We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZROZ icon
351
PIMCO 25+ Year Zero Coupon US Treasury Index Exchange-Traded Fund
ZROZ
$1.28B
– –
-3,000
Closed -$225K
ZVRA icon
352
Zevra Therapeutics
ZVRA
$686M
– –
-2,000
Closed -$9.8K
ZVSA
353
DELISTED
ZyVersa Therapeutics
ZVSA
– –
-9,598
Closed -$36.1K
SBCWW
354
SBC Medical Group Warrants
SBCWW
– –
-19,800
Closed -$1.41K
IROHU
355
DELISTED
Iron Horse Acquisitions Corp Unit
IROHU
– –
-25,000
Closed -$257K
AIEV
356
DELISTED
Thunder Power Holdings, Inc. Common Stock
AIEV
– –
-1,500
Closed -$2.48K
AITRU
357
DELISTED
AI Transportation Acquisition Corp Unit
AITRU
– –
-7,500
Closed -$78.8K
EGRX
358
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-22,000
Closed -$123K
NNAGU
359
DELISTED
99 Acquisition Group Inc Unit
NNAGU
– –
-7,500
Closed -$80.5K
KCGI
360
DELISTED
Kensington Capital Acquisition Corp. V
KCGI
– –
-8,500
Closed -$94.2K
CERE
361
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-93,350
Closed -$3.82M
CERE
362
PUT
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-50,200
Closed -$2.05M
CETUW
363
DELISTED
Cetus Capital Acquisition Corp. Warrant
CETUW
– –
-5,000
Closed -$130
ARYD
364
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-53,527
Closed -$614K
CETUR
365
DELISTED
Cetus Capital Acquisition Corp. Right
CETUR
– –
-4,999
Closed -$1.42K
BKHAU
366
Black Hawk Acquisition Corp Units
BKHAU
$85.5M
– –
-15,000
Closed -$155K
11 12 13 14
15

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.